MedTrace Logo

Impact of Chemokine Receptor 5 (CCR5) Inhibition on Sarcoidosis Immunophenotypes

NCT02134717 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2025-12-03

Study results available
· View outcomes & findings →

Summary

The study hypothesizes that inhibition of the receptor CCR5 by maraviroc will diminish inflammation in patients with sarcoidosis. Subjects with active sarcoidosis will first undergo bronchoscopy with bronchoalveolar lavage to recover lung immune cells for baseline analysis. They will then receive the drug maraviroc for 6 weeks duration. They will then undergo a repeat bronchoscopy with bronchoalveolar lavage to recover lung immune cells for analysis following maraviroc treatment.

Conditions

  • Sarcoidosis

Interventions

DRUG

all subjects will receive maraviroc 300mg orally twice a day for 6 weeks

PROCEDURE

Bronchoscopy with bronchoalveolar lavage

Bronchoscopy employs a flexible instrument that is inserted into the trachea and proximal airways after topical anesthesia. Bronchoalveolar lavage involves the instillation of saline solution through the bronchoscope into the airways followed by recovery under suction to collects lung fluid containing cells and proteins.

PROCEDURE

venipunctures

Venipunctures will be performed at study entry, after two weeks, and at the end of the study to collect blood for research studies and safety laboratories.

PROCEDURE

Skin biopsy

For subjects with sarcoidosis skin lesions, an optional skin biopsy specimen may be collected for research studies.

Sponsors & Collaborators

  • University of Pittsburgh

    collaborator OTHER

  • Kevin F. Gibson

    lead OTHER

Principal Investigators

  • Kevin F Gibson, MD · DorothyP. and Richard P. SImmons Center for Interstitial Lung Disease at the University of Pittsburgh

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2015-05-31
Completion
2015-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02134717 on ClinicalTrials.gov